Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lineage Cell Therapeutics Inc

1.80
-0.1600-8.16%
Post-market: 1.890.0892+4.96%18:16 EST
Volume:3.03M
Turnover:5.63M
Market Cap:411.04M
PE:-9.72
High:1.97
Open:1.96
Low:1.80
Close:1.96
52wk High:2.09
52wk Low:0.3651
Shares:228.36M
Float Shares:177.83M
Volume Ratio:1.27
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1852
EPS(LYR):-0.0930
ROE:-71.51%
ROA:-13.17%
PB:8.50
PE(LYR):-19.36

Loading ...

Lineage Cell Therapeutics Inc. to Report Third Quarter 2025 Results

Reuters
·
Oct 30

Robert W. Baird Sticks to Its Buy Rating for Lineage Therap (LCTX)

TIPRANKS
·
Sep 24

Lineage Cell Therapeutics Expands into Type 1 Diabetes with New Islet Cell Transplant Program

Reuters
·
Sep 08

Lineage Cell Therapeutics Initiates Cell Transplant Program in Type 1 Diabetes

THOMSON REUTERS
·
Sep 08

Lineage Cell Therapeutics Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference

Reuters
·
Sep 02

Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 27

Sector Update: Health Care Stocks Rise Tuesday Afternoon

MT Newswires Live
·
Aug 27

Lineage Cell Therapeutics Partners with William Demant Invest to Advance Hearing Loss Treatment Through ReSonance™ Development

Reuters
·
Aug 26

Lineage Cell Therapeutics Inc - William Demant Invest to Contribute up to $12 Mln

THOMSON REUTERS
·
Aug 26

Lineage Announces Research Collaboration With William Demant Invest to Develop Resonance™ (Anp1) for Hearing Loss

THOMSON REUTERS
·
Aug 26

Lineage Cell Therapeutics Reports Q2 2025 Results: Revenues Rise to $2.8M, Net Loss Widens to $30.5M, EPS Drops to $0.13

Reuters
·
Aug 13

Press Release: Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Dow Jones
·
Aug 13

Lineage Cell Therapeutics Announces First Patient Dosed in Innovative Study of OPC1 for Spinal Cord Injury

Reuters
·
Aug 04

Lineage Cell Therapeutics Inc. Concluded Annual Shareholder Meeting

Reuters
·
Jul 03

Lineage Cell Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 23

BRIEF-Opregen® 36-Month Visual Acuity Results Featured At Clinical Trials At The Summit 2025

Reuters
·
Jun 23

Lineage Cell Therapeutics Announces Promising 36-Month Results from OpRegen Cell Therapy Trial for Geographic Atrophy in AMD Patients

Reuters
·
Jun 23

Lineage Cell Therapeutics Inc. Appoints Baker Tilly as New Auditor Following Merger with Moss Adams

Reuters
·
Jun 10

Lineage Cell Therapeutics Inc. to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

Reuters
·
May 14

BRIEF-Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update

Reuters
·
May 14